Genetic Technologies (Genetic Technologies) 3-Year FCF Growth Rate : 11.40% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies 3-Year FCF Growth Rate?

Genetic Technologies's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.19.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 11.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 22.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 28.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Genetic Technologies was 82.90% per year. The lowest was -97.70% per year. And the median was 18.60% per year.

Competitive Comparison of Genetic Technologies's 3-Year FCF Growth Rate

For the Diagnostics & Research subindustry, Genetic Technologies's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's 3-Year FCF Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's 3-Year FCF Growth Rate falls into.

Genetic Technologies 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Genetic Technologies (NAS:GENE) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Genetic Technologies 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.